Everything below concerns angiotensin IV. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-12-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic angiotensin IV analog | Peptidomimetic |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in DMSO; limited in water | Typical for small peptides |
| Storage | -20 °C, desiccated | Protect from light and moisture |
| Analytical method | HPLC with UV detection | Purity and identity checks |
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
== External links == "Melanocortin Receptors: MC3". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology. This article incorporates text from the United States National Library of Medicine, which is in the public domain.
== Causes == Conditions that chronically increase the pressure within the abdomen can predispose people to uterine prolapse. This includes chronic obstructive pulmonary disease (COPD), obesity, chronic cough, straining due to chronic constipation, and repetitive heavy lifting. Tobacco smoking has been found to be correlated to pelvic organ prolapse both due to the risk of developing lung conditions that lead to chronic cough or COPD as well as the negative effects of tobacco chemicals on connective tissue.
== Function == The abundance and ubiquity indicate that TCTP may have important primary functions. However, a large number of cellular and biochemical functions have been found since 1980s. Most of these functions can be classified into three groups.
Acute toxicity The oral LD50 range of aflatoxin B1 is estimated to be 0.3–17.9 mg/kg body weight for most animal species. For instance, the oral LD50 of aflatoxin B1 is estimated to be 17.9 mg/kg body weight in female rats and 7.2 mg/kg body weight in male rats. Still in male rats, the intraperitoneal LD50 of aflatoxin B1 is estimated to be 6.0 mg/kg body weight. Symptoms include anorexia, malaise, and low-grade fever. Subacute toxicity Subacute toxicity studies of aflatoxin B1 in animals showed moderate to severe liver damage. In monkeys for instance, subacute toxicity studies showed portal inflammation and fatty change. Chronic toxicity Chronic toxicity studies of aflatoxin B1 in chickens showed decreased hepatic microsomal cytochrome P-450 concentration, reduction in feed consumption and decreased weight gain. Subchronic toxicity Subchronic toxicity studies of aflatoxin B1 in fish showed fish to present with preneoplastic lesions, concurrently with changes in gill, pancreas, intestine and spleen. Genotoxicity Treatment of human liver cells with aflatoxin B1 at doses that ranged from 3–5 μmol/L resulted in the formation of aflatoxin B1-DNA adducts, 8-hydroxyguanine lesions and DNA damage. Carcinogenicity The carcinogenicity of aflatoxin B1, which is characterized by the development of liver cell carcinoma, has been reported in rat studies. Embryotoxicity Embryonic death and impaired embryonic development of the bursa of Fabricius in chickens by aflatoxin B1 has been reported.
Sources: en.wikipedia.org
=== Second week (28 February – 6 March) === On 28 February, clashes between Pakistan border guards and Afghan Taliban were reported along the border areas of Torkham. Later on, an airstrike was carried out by the PAF on Jalalabad Airport, the capital of Nangarhar province. An AFP journalist reported hearing sounds of two loud explosions from the direction of Jalalabad airport. Pakistan's media outlet also reported an airstrike in Nangarhar province targeting several Taliban headquarters. On the same day, Afghan forces claimed a Pakistani fighter was shot down over Jalalabad using anti-aircraft guns, with the pilot captured alive. Pakistan rejected the Afghan Taliban's claim, labeling it as wartime propaganda. Afterwards, the detained individual was severely beaten by the Afghan Taliban and locals, while being paraded through the market area in Jalalabad, with Taliban officials terming the event as an important war operation. However, later on, it was revealed that the pilot that Afghan forces captured was an ordinary Afghan national who was a parachutist and had no connection to the Pakistani army. Further investigation also revealed that news of downing a fighter jet was false, and the detained individual was later released.
== Wet-aged beef == Wet-aged beef is beef that has typically been aged in a vacuum-sealed bag to retain its moisture. Since the 1970s, with the development of vacuum packing machines and related technology, this has become the dominant mode of aging beef in the US and UK. It is popular with producers, wholesalers and retailers because it takes less time: typically only a few days and there is no moisture loss, so any given piece of meat sold by weight will have a higher value than a dry aged piece where moisture loss is desired for taste at the expense of final weight. The beef is usually kept for a period of 4 to 10 days in wet aging. Modified-atmosphere packaging (MAP) is usually employed for the vacuum packaging of meat; typically between 60 and 80 percent oxygen to retain its appetizing color, with red meat such as beef needing a higher oxygen level than less vividly colored meat such as pork. The vacuum packed beef is stored at a temperature of 32 to 45 °F (0 to 7 °C).
The unique dissociation patterns help discover the Quaternary structure of the complex. The symmetric charge distribution and dissociation dependence are unique to SID and make the spectra produced distinctive from any other dissociation technique. The SID technique is also applicable to ion-mobility mass spectrometry (IM-MS). Three different methods for this technique include analyzing the characterization of topology, intersubunit connectivity, and the degree of unfolding for protein structure. Analysis of protein structure unfolding is the most commonly used application of the SID technique. For Ion-mobility mass spectrometry (IM-MS), SID is used for dissociation of the source activated precursors of three different types of protein complexes: C-reactive protein (CRP), transthyretin (TTR), and concanavalin A (Con A). This method is used to observe the unfolding degree for each of these complexes. For this observation, SID showed the precursor ions' structures that exist before the collision with the surface. IM-MS utilizes the SID as a direct measure of the conformation for each proteins' subunit. Fourier-transform ion cyclotron resonance are able to provide ultrahigh resolution and high mass accuracy to instruments that take mass measurements. These features make FT-ICR mass spectrometers a useful tool for a wide variety of applications such as several dissociation experiments such as collision-induced dissociation (CID, electron transfer dissociation (ETD), and others.
BCAAs also inhibit uptake of tyrosine, a precursor of catecholamines such as dopamine and norepinephrine, potentially depressing catecholamine synthesis. Because both serotonin and catecholamines influence exercise capacity, their simultaneous reduction may explain the relatively neutral net effect of BCAA supplementation on performance. BCAA supplementation also alters nitrogen metabolism. During exercise, serum ammonia levels increase, contributing to both muscular and central fatigue. In muscle, high ammonia enhances phosphofructokinase (PFK) activity, further increasing lactic acid production. BCAAs enhance glutamine synthesis, which consumes ammonia and limits its accumulation. Excess ammonia in the brain reduces levels of GABA and glutamate, promoting central fatigue. Finally, BCAA supplementation has been associated with reduced levels of creatine kinase in muscle following exercise, an indicator of reduced muscle damage. Creatine kinase transfers phosphate groups from ATP to form phosphocreatine, which buffers cellular energy supply. Meta-analyses suggest BCAA supplementation may lower creatine kinase levels and attenuate DOMS.
=== Abuse of Coalition POWs === During the conflict, coalition aircrew shot down over Iraq were displayed as prisoners of war on TV, most with visible signs of abuse. Amongst several testimonies to poor treatment, USAF Captain Richard Storr was allegedly tortured by Iraqis during the Persian Gulf War. Iraqi secret police broke his nose, dislocated his shoulder and punctured his eardrum. Royal Air Force Tornado crew John Nichol and John Peters have both alleged that they were tortured during this time. Nichol and Peters were forced to make statements against the war on television. Members of British Special Air Service Bravo Two Zero were captured while providing information about an Iraqi supply line of Scud missiles to coalition forces. Only one, Chris Ryan, evaded capture while the group's other surviving members were violently tortured. Flight surgeon (later General) Rhonda Cornum was sexually assaulted by one of her captors after the Black Hawk helicopter in which she was riding was shot down while searching for a downed F-16 pilot.
Sources: en.wikipedia.org
=== Cor–Cz === Robert Corey (1897–1971). American protein chemist at Caltech, known for work with Linus Pauling on the α-helix and β-sheet. Member Natl. Acad. Sci. USA. Carl Ferdinand Cori (1896–1984). American biochemist at Washington University and Albert Einstein College of Medicine, who worked on glycogen. Nobel Prize in Physiology or Medicine (1947). Member Natl. Acad. Sci. USA. Gerty Cori (1896–1957). Czech-American biochemist at Washington University, known for glycogen research. Nobel Prize in Physiology or Medicine (1947). Athel Cornish-Bowden (b. 1943). British enzymologist at the CNRS, Marseille. He has contributed to the development of metabolic control analysis, and is the author of Fundamentals of Enzyme Kinetics. Suzanne Cory (b. 1942). Australian molecular biologist known fotr work on the genetics of the immune system, at the Walter and Eliza Hall Institute of Medical Research, Melbourne. Peter Coveney (b. 1958). British Computational molecular biology specialist at University College London, University of Amsterdam and Yale. Nicholas R. Cozzarelli (1938–2006). American biochemist at UC Berkeley, and former editor-in-chief of the Proceedings of the National Academy of Sciences. Member Natl. Acad. Sci. USA. Gerald Crabtree (b. 1946). American biochemist at Stanford, known for defining the Ca2+-calcineurin-NFAT signalling pathway, pioneering the development of synthetic ligands for regulation of biological processes. Robert K. Crane (1919–2010).
== Description == The death cap has a large and imposing epigeous (aboveground) fruiting body (basidiocarp), usually with a pileus (cap) from 5 to 15 cm across (2 to 5.8 inches) across, initially rounded and hemispherical, but flattening with age. The color of the cap can be pale-green, yellowish-green, olive-green, bronze, or (in one form) white; it is often paler toward the margins, which can have darker streaks; it is also often paler after rain. The cap surface is sticky when wet and easily peeled—a troublesome feature, as that is allegedly a feature of edible fungi. The remains of the partial veil are seen as a skirtlike, floppy annulus usually about 1 to 1.5 cm (3⁄8 to 5⁄8 in) below the cap. The crowded white lamellae (gills) are free. The stipe is white with a scattering of grayish-olive scales and is 8 to 15 cm (3+1⁄8 to 5+7⁄8 in) long and 1 to 2 cm (3⁄8 to 3⁄4 in) thick, with a swollen, ragged, sac-like white volva (base). As the volva, which may be hidden by leaf litter, is a distinctive and diagnostic feature, it is important to remove some debris to check for it. Spores: 7-12 x 6-9 μm. Smooth, ellipsoid, amyloid. The smell has been described as initially faint and honey-sweet, but strengthening over time to become overpowering, sickly-sweet and objectionable. Young specimens first emerge from the ground resembling a white egg covered by a universal veil, which then breaks, leaving the volva as a remnant. The spore print is white, a common feature of Amanita.
== Release == To promote Half-Life, Valve's chief marketing officer, Monica Harrington, promoted Valve's reputation in the industry, with conference talks about their advances in game development, leading to coverage in the Wall Street Journal. Half-Life was released on November 19, 1998. When Sierra told Valve it was not planning to promote it beyond launch, Harrington threatened that Valve would "walk away from our agreement and tell the industry that had fallen in love with Valve how screwed up Sierra really was". In response, Sierra reissued Half-Life in a "Game of the Year" edition, boosting sales. In 2001, after renegotiating with Sierra, Valve gained the Half-Life intellectual property and online distribution rights for its games. Valve released two Half-Life demos. The first, Half-Life: Day One, contained the first fifth of the game and was distributed with certain graphic cards. The second, Half-Life: Uplink, was released on February 12, 1999, and featured original content. A short film based on Half-Life, also titled Half-Life: Uplink, was developed by Cruise Control, a British marketing agency, and released on February 11. The protagonist is a journalist who infiltrates the Black Mesa Research Facility, trying to discover what has happened there. Half-Life was censored in Germany to comply with the Federal Department for Media Harmful to Young Persons, which regulates depictions of violence against humans. Valve replaced the human characters with robots, spilling oil and gears instead of blood and body parts when killed, among other changes.
=== Off-label uses === In 2012, pharmaceutical company Abbott paid $1.6 billion in fines to US federal and state governments for illegal promotion of off-label uses for Depakote, including the sedation of elderly nursing home residents. Some studies have suggested that valproate may reopen the critical period for learning absolute pitch and possibly other skills such as language.
Sources: en.wikipedia.org
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.
No major drug regulatory agency has approved dihexa for human use. Published human clinical trials are absent, so its safety and efficacy are not established. It is commonly sold for laboratory research only.
It was developed from research on angiotensin IV analogs and peptide stability. The goal was to find compounds with better brain penetration and metabolic resistance. Early studies used rodent models rather than human participants.
Liquid chromatography–mass spectrometry is commonly used. It provides molecular mass and purity information. Other methods may include HPLC with ultraviolet detection.